Logo
Logo

About Ciprofloxacin Hydrochloride API

Product
  • Therapeutic Category抗感染

  • API Technology

    Synthetic

  • Dose Form

    Oral Solids

  • Dr Reddy's Development Status

    Available (Commercial)

作用机制

The bactericidal action of ciprofloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV (both Type II topoisomerases), which are required for bacterial DNA replication, transcription, repair, and recombination.

适应症

CIPRO is a fluoroquinolone antibacterial indicated in adults (18 years of age and older) with the following infections caused by designated, susceptible bacteria and in pediatric patients where indicated:
• Skin and Skin Structure Infections
• Bone and Joint Infections
• Complicated Intra-Abdominal Infections
• Infectious Diarrhea
• Typhoid Fever (Enteric Fever)
• Uncomplicated Cervical and Urethral Gonorrhea
• Inhalational Anthrax post-exposure in adult and pediatric patients
• Plague in adult and pediatric patients
•  Chronic Bacterial Prostatitis
•  Lower Respiratory Tract Infections
o Acute Exacerbation of Chronic Bronchitis
•  Urinary Tract Infections
o Urinary Tract Infections (UTI)
o Acute Uncomplicated Cystitis
o Complicated UTI and Pyelonephritis in Pediatric Patients
•  Acute Sinusitis

Usage
To reduce the development of drug-resistant bacteria and maintain the effectiveness of CIPRO and other antibacterial drugs, CIPRO should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria

Dr. Reddy's的专长

Dr. Reddy's总部位于印度海得拉巴,是全球领先的活性药物成分(API)供应商之一。 Dr. Reddy's的API业务是美国、欧洲、巴西、拉丁美洲、日本、中国、韩国和新兴市场的制药公司的首选合作伙伴。

Dr. Reddy's博士的API业务在过去30多年来在开发和制造复杂API(如类固醇,多肽,复杂长链分子和高效API(HPAPI /肿瘤药物))方面所建立的深厚技术优势中茁壮成长。 我们在知识产权和法规事务方面的实力可以帮助我们始终如一地达到并超越监管标准,从而为这一专业知识提供补充。 Dr. Reddy's博士 盐酸环丙沙星 API是研发,知识产权和监管方面广泛专业知识的结果。

帮助我们的客户率先进入市场的关键组成部分是响应式供应链。 我们通过确保所有设施都高效运行并达到最新的质量,安全和生产率标准来实现这一目标。 业务和工厂之间的强大互联可以快速响应动态的市场变化,从而避免短缺并满足需求的突然激增。

RFQ Form

Phone

FAQs

Disclaimer: Products under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act (Bolar Exemption) and not for commercial sale.